The official journal of the Brazilian Retina and Vitreous Society
Future of anti-VEGF: biosimilars and biobetters
The advent of Anti- VEGFs like Lucentis (Ranibizumab), Eylea (Aflibercept) and off-label Avastin (Bevacizumab) have radically improved visual outcomes in patients of neovascular Age Related Macular Degeneratio...